44
Participants
Start Date
November 18, 2018
Primary Completion Date
January 27, 2021
Study Completion Date
June 25, 2021
etrumadenant
Etrumadenant is an A2aR and A2bR antagonist.
mFOLFOX
Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
The Kinghorn Cancer Centre, Darlinghurst
Chris O'Brien Lifehouse, Camperdown
Macquarie University Hospital, Macquarie Park
St. George Private Hospital, Kogarah
Border Medical Oncology, Albury
Cabrini Hospital, Malvern
Peninsula & South Eastern Haematology and Oncology Group, Frankston
UPMC Hillman Cancer Center, Pittsburgh
Maryland Oncology Hematology, Rockville
Virginia Cancer Specialists, PC, Fairfax
Carolina BioOncology Institute, Huntersville
Prisma Health, Greenville
QUEST Research Institute, Farmington Hills
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology - Tyler, Tyler
Texas Oncology - Fort Worth Cancer Center, Fort Worth
Texas Oncology - San Antonio Northeast, San Antonio
Texas Oncology - San Antonio Medical Center, San Antonio
Texas Oncology - Austin Midtown, Austin
Rocky Mountain Cancer Centers, Denver
Arizona Clinical Research Center, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
Yale Cancer Center, New Haven
Dana Farber Cancer Institute, Boston
Lead Sponsor
Arcus Biosciences, Inc.
INDUSTRY